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S U M M A R Y
Background: We assessed the incidence of and risk factors for tuberculin skin test (TST) conversion
among HIV-infected adults at a New York City clinic.
Methods: All adult HIV-infected patients were eligible for inclusion if they had a negative baseline TST
result and at least one subsequent documented TST test result.
Results: A total of 414 HIV-infected patients had a negative baseline TST result; 288 (69.6%) were male.
Among 348 patients who had a place of birth documented, 50% were born outside of mainland USA.
Twenty-two (5.3%) of 414 patients had documented TST conversions, giving a crude incidence rate of
1.77 per 100 person-years. Being a foreign-born Asian individual (p = 0.02), having lived in a shelter
(p = 0.004), and having an increase in CD4 cell count (p = 0.02) while under care were independent risk
factors for TST conversion.
Conclusions: We found a high TST conversion rate among HIV-infected patients attending an urban
clinic. Annual TST testing is particularly important for patients who are foreign-born from high-endemic
countries, those with a history of homelessness, and those with an increase in CD4 cell count since the
baseline negative TST test.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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HIV-infected individuals are 10 times more likely than HIV-
uninfected individuals to progress from latent tuberculosis
infection (LTBI) to active tuberculosis (TB).1 Due to the high rate
of progression and greater severity of TB disease among HIV-
infected individuals, diagnosis and treatment of LTBI in this
population is critical.2 Despite many limitations, the tuberculin
skin test (TST) remains the primary diagnostic tool for LTBI,
including for HIV-infected persons.
The New York State Department of Health AIDS Institute’s HIV
Quality of Care Program (HIVQUAL) is responsible for the
systematic monitoring of the quality of medical care provided to
people with HIV infection in New York’s hospitals, chronic care
facilities, and community-based organizations.3 One quality
indicator required of clinics that receive funding from Ryan White
grants is an annual TST for all HIV-infected patients.3 However, few
data exist on the incidence of TST conversion and associated risk* Corresponding author. Tel.: +1 212 263 0766.
E-mail address: Sumathi.sivapalasingam@gmail.com (S. Sivapalasingam).
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http://dx.doi.org/10.1016/j.ijid.2012.03.002factors in HIV-infected patients,4 and none in a non-study clinic
setting. The aim of this study was to assess the incidence of TST
conversion and to identify risk factors for conversion among
patients attending our HIV clinic in New York City.
2. Methods
All adult HIV-infected patients (age 18 years) were eligible for
inclusion if they had attended the Bellevue Hospital Center’s
Virology Clinic at least twice between January 1, 1995 and
December 31, 2006. The initial cohort identiﬁed from this search
included 1047 patients. This research protocol was reviewed by
the New York University School of Medicine Institutional Review
Board and ruled exempt because it was a retrospective chart
review conducted in such a way that the subjects could not be
identiﬁed directly or through identiﬁers linked to the subjects.
We reviewed paper and electronic charts, including clinic,
emergency room, and inpatient visits, using a standardized data
collection form. Fifty-nine charts (5.6%) were unavailable for
review and therefore excluded. Among the patients with available
charts (n = 988), patients were excluded if they had no record of a
TST test result in their medical chart (n = 286, 28.9%), had an initialses. Published by Elsevier Ltd. All rights reserved.
Table 1
Baseline characteristics of patients with negative baseline tuberculin skin testing
(n = 414)
Characteristic
Male sex, n (%) 288 (70)
Median age, years (range) 42 (19–71)
Race, n (%)
Black 150 (36)
Hispanic 172 (42)
Asian/Paciﬁc Islander 30 (7)
White 42 (10)
Unknown 20 (5)
Birthplace, n (%)
Mainland USA (not including Puerto Rico) 174 (42)
Outside of mainland USA (including Puerto Rico) 174 (42)
Unknown 66 (16)
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(n = 18, 1.8%). Of the remaining 583 patients with a negative initial
TST result, 169 (29.0%) were excluded because they had no further
TST testing. The remaining 414 patients who had a negative
baseline TST result and at least one subsequent TST test
documented were included in this analysis.
Data abstracted included gender, age, race, birthplace, and year
of arrival to the USA (if foreign-born). History of vaccination with
bacillus Calmette–Gue´rin (BCG) was not routinely recorded and
therefore not included in the study. Information was collected at
baseline and again at the time of each subsequent TST test on: (a)
HIV history, including CD4 cell count, HIV viral load, and receipt of
antiretroviral therapy, and (b) known risk factors for TST
conversion, including history of living in a shelter, history of
incarceration, history of living in a group home, history of being a
home health aide or healthcare provider, exposure to a person with
known active TB, and alcohol or drug dependence.
The standard operating procedure was to perform an annual
TST on all HIV-infected persons during their comprehensive exam,
regardless of risk of TB infection, and after a possible exposure to a
person with active TB. The two-step TST was not routinely
conducted. TSTs were performed by intra-dermal injection using 5
TU intermediate strength puriﬁed protein derivative. Induration
was measured 48–72 h after inoculation. A physician conﬁrmed all
skin reactions suspected to be positive. Induration with a
transverse diameter of 5 mm or greater was considered positive.
Patient-read results were not counted. A TST conversion was
deﬁned by the development of a TST with 5 mm induration after
a previously negative test (<5 mm).4
For non-converters, the time at risk for TST conversion was
estimated as the interval between the ﬁrst and last tests. For the
converters, the time at risk was the interval from the ﬁrst to last
negative test plus half the interval from the last negative to the ﬁrst
positive test. The impact of a rise in CD4 cell count on risk of
conversion during the period of observation was assessed by
computing the change from the ﬁrst to last CD4 count for all
persons who had at least two CD4 cell counts taken at least 90 days
apart. The last CD4 count used in the analysis was the most recent
test for non-converters and the test closest to the date of
conversion for the converters.
Final analyses were done using either SPSS v.12 (IBM-SPSS,
Chicago, IL, USA) or the statistical environment ‘R’ (http://
www.r-project.com). Survival curves were estimated by the
method of Kaplan and Meier, and hazard ratios were estimated
using Cox proportional hazards regression. Baseline risks were
considered as time-invariant factors and interval risks recorded
at the time of each TST were considered as time-dependent
factors. The curves and ratios were compared using the log rank
test. Nested regression models containing both time-invariant
and time-dependant factors were compared to reduced models
by assessing the change in deviance using an F ratio or Chi-
square test. Means of continuous variables were compared using
the Student’s t-test and medians were compared using the
Wilcoxon signed-rank test.
3. Results
Among the 414 HIV-infected patients with a negative baseline
TST result, 288 (69.6%) were male (Table 1). The median age was 42
years (interquartile range (IQR) 36–50 years), and men were
signiﬁcantly older than women (means 43.9 vs. 40.2 years,
p = 0.0005). Of the 394 patients with a race or ethnicity recorded,
172 (43.7%) were identiﬁed as Hispanic, 150 (38.1%) as black, 42
(10.6%) as white, and 30 (7.6%) as Asian (Table 1). Among 348
patients who had place of birth documented, 174 (50%) were born
outside of mainland USA.3.1. TST conversion
Twenty-two (5.3%) of 414 patients had documented TST
conversions. The 22 patients who converted were at risk for
47.99 person-years and the 392 non-converters were at risk for
1193.48 person-years. Overall, the incidence of TST conversion was
1.77 per 100 person-years at risk. The incidence of TST conversion
among men was 1.73 conversions per 100 person-years observa-
tion (15 conversions in 865.05 person-years) and among women
was 1.88 conversions per 100 person-years observation (7
conversions in 371.82 person-years). Twenty-ﬁve percent of
patients were observed for more than 3.9 years, 50% for 2.8 years
or more, and 75% for 1.6 years or more. Among the 22 persons who
converted their TST, nine (41%) converted on their second TST, nine
(41%) on their third TST, two (9%) on their fourth TST, one (5%) on
their ﬁfth TST, and one (5%) on their sixth TST. The median interval
between tests was 412 days (IQR 330–611) and there was no
evidence that this interval changed as the number of prior TSTs
increased.
3.2. Risk factors for TST conversion
Patients who identiﬁed themselves as Asian had a higher rate of
TST conversion (Table 2, Figure 1A). The omnibus log rank test for
race was signiﬁcant (log rank Chi-square = 14.2, degree of freedom
(df) = 4, p = 0.007) and became non-signiﬁcant when Asians were
removed from the analysis. Being foreign-born was also a
signiﬁcant risk factor (log rank Chi-square = 5.5, df = 1,
p = 0.019) and became non-signiﬁcant when Asians, all of whom
were foreign-born, were removed from the analysis (log rank Chi-
square = 3.0, df = 1, p = 0.08).
Patients who experienced a TST conversion had a non-
signiﬁcantly lower baseline median CD4 cell count compared to
non-converters: 100 cells/ml (IQR 0–564) vs. 278 cells/ml (IQR 80–
460) (p = 0.21). Among the converters, by the time of TST
conversion, the median CD4 cell count had risen to 482 cells/ml
(IQR 323–662). Three hundred and seventy-three persons had at
least two CD4 tests conducted 90 or more days apart (median
interval from ﬁrst to last CD4 test was 995 days (IQR 558–1361)).
Among these 373 persons, 124 (33.2%) had a decline or no change
in the CD4 cell count from baseline (mean 134.4 (SD 139.9)) and
249 (66.8%) had an increase (mean 203.7 (SD 171)). Patients with
increases in the CD4 cell count had a signiﬁcantly higher TST
conversion rate compared to those with no increase or a decrease
in CD4 cell count (relative hazard 7.64, log rank Chi-square = 5.4,
df = 1, p = 0. 02) (Figure 1B). The median increase in CD4 count for
converters was 223 (IQR 113–275) and for non-converters it was
63.5 (IQR 36.5–214.5) (p = 0.009).
Patients with a history of having ever lived in a shelter had a
higher rate of conversion (relative hazard = 3.49, p = 0.004)
Table 2
Tuberculin skin test (TST) conversion rates and risk factors for conversion
Risk factor for TST conversion Conversions/
at risk
HR (95% CI) p-Value
Ever lived in shelter?
Yes 7/48 3.49 (1.42–8.57) 0.004
No 15/366
Race 0.007
White 1/42 1
Hispanic 6/172 1.03 (0.124–8.63)
Black 9/150 1.90 (0.24–15.13)
Asian/Paciﬁc Islander 6/30 6.05 (0.7–50.35)
Born in USA (including Asian race)
Not mainland USA 15/174 3.46 (1.15–10.4) 0.019
Mainland USA 4/174
Change in CD4 cell count
Increased during period 16/249 7.64 (1.01–57.7) 0.020
Decreased during period 1/124
Born in USA (excluding Asian race)
Not USA 10/147 2.67 (0.837–8.54) 0.084
USA (not Puerto Rico) 4/174
Initial viral load
<50 copies/ml 5/118 2.71 (0.725–10.1) 0.123
50 copies/ml 4/211
Any alcohol dependence?
Yes 3/103 0.48 (0.14–1.62) 0.219
No 19/311
Any recreational drug use?
Yes 7/181 0.60 (0.25–1.47) 0.261
No 15/233
Ever lived in a group home?
Yes 1/23 0.74 (0.1–5.48) 0.765
No 21/391
Age by quartile, years 0.382
19–36 10/117 1
37–42 5/93 0.76 (0.26–2.25)
43–50 5/105 0.63 (0.22–1.88)
51–71 2/99 0.28 (0.061–1.30)
Sex
Female 7/126 1.09 (0.45–2.68) 0.846
Male 15/288
Ever incarcerated?
Yes 3/51 1.10 (0.32–3.71) 0.883
No 19/363
HR, hazard ratio; 95% CI, 95% conﬁdence interval.
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time-dependant information to the baseline information on shelter
residence increased the hazard ratio slightly (to 3.6), but the
increase was not signiﬁcant (deviance = 0.364, df = 1, p = 0.50).
Age, gender, prior or interval of intravenous drug use, alcohol
dependence, incarceration, living in a group home, exposure to a
person with known tuberculosis, receiving antiretroviral therapy
at the time of initial visit, and having an undetectable HIV viral loadFigure 1. Kaplan–Meier estimates of the probability of remaining tuberculin skin test (TST
history of living in a homeless shelter.(<50 copies per ml) at the time of the initial visit were not
associated with an increased risk of TST conversion.
4. Discussion
Conversion of a TST from a negative to a positive in an HIV-
infected patient may occur because of new TB infection, a boosting
effect, or improved TB-speciﬁc immune responses.2 We found that
among HIV-infected patients attending a municipal clinic in New
York City, the incidence of TST conversion was 1.77 cases per 100
person-years at risk. Being a foreign-born person of Asian ethnicity,
having ever lived in a homeless shelter, and having an increase in
CD4 cell count were each an independent risk factor for TST
conversion.
The incidence of TB cases in the USA decreased by 45% between
1993 and 2006.5 This decline has occurred disproportionately
among the US-born population; in 2006, 57% of all reported TB
cases were among foreign-born persons.5 A recent study found that
53% of TB cases among foreign-born persons occurred in persons
from sub-Saharan Africa and Southeast Asia.6 Our study found that
being Asian was a signiﬁcant risk factor for TST conversion.
Furthermore, when Asians were taken out of the analysis, being
foreign-born was no longer an independent risk factor. This and the
previously cited data6 support the recommendation that annual
testing be administered to persons born in countries with a high
burden of TB rather than all foreign-born individuals.2
Many persons born in TB-endemic countries receive BCG
vaccination during childhood and therefore may react to a TST
even without exposure to Mycobacterium tuberculosis.7 The
tuberculin reactivity in BCG-vaccinated individuals does wane
over time but can be boosted by the TST. A two-step TST entails a
second test conducted 1 to 4 weeks after the ﬁrst negative TST to
identify those who have an attenuated but existing immunologic
recall of the tuberculosis antigen. A positive result after an initial
negative result in a two-step test is referred to as the ‘booster
phenomenon’. A subsequent positive TST result after a negative
two-step TST result is assumed to represent a true conversion. In
the present study, because BCG vaccination history was not
recorded and two-step testing was not systematically recorded, we
cannot conﬁdently rule out a boosting effect as a contributing
factor to the higher rates of conversion we observed among
foreign-born patients. Nevertheless, the high incidence of active TB
infection among foreign-born persons places them at great risk of
being exposed to TB. Therefore, foreign-born HIV-infected patients
with a new TST conversion would require LTBI treatment
regardless of BCG vaccination history.
Homelessness and living in shelters are known risks for TB.2,8,9
Our ﬁndings support recommendations for annual TST testing in)-negative for HIV-infected patients by (A) race, (B) change in CD4 cell count, and (C)
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practice, this would include conducting annual TST testing not only
in those who are currently homeless or living in shelters, but in
patients who have a history of homelessness or are intermittently
homeless.
Restoration of M. tuberculosis-speciﬁc immune function with
antiretroviral therapy occurs10 and may lead to TST conversion in
patients receiving HIV treatment. The current recommendation to
re-administer a TST after the CD4 cell count increases to above 200
cells/ml is based on expert opinion.2 A recent study revealed that
recent initiation of highly active antiretroviral therapy (HAART)
(within 2 years) and not any speciﬁc CD4 threshold was a risk
factor for TST conversion.4 We found that patients who had an
increase in CD4 count while under observation were more likely to
experience a TST conversion compared to patients whose CD4
count did not increase or decreased since the baseline TST. The
median increase in CD4 cell count among converters was 223 cells/
ml compared to 63.5 cells/ml among non-converters. Furthermore,
the median CD4 count at baseline was 100 cells/ml compared to
482 cells/ml at the time of conversion, supporting the recom-
mendations for repeat TST after CD4 cell counts rise to above 200
cells/ml.
Although the New York State AIDS Institute’s HIVQUAL program
recommends annual TSTs in all HIV-infected patients, guidelines
written by the US Public Health Service and the Infectious Diseases
Society of America (IDSA) recommend initial TST for all HIV-
infected patients and annual skin testing only for those patients at
high risk for exposure to tuberculosis and those whose immune
function has improved in response to antiretroviral therapy.11
The incidence of TST conversion among women in our study, 1.9
conversions per 100 person-years observation (7 conversions in
371.82 person-years), is signiﬁcantly higher than the rate of 0.8
conversion per 100 person-years (36 conversions within 4416
person-years observation, p = 0.037) previously reported among
HIV-infected women enrolled in the Women’s Interagency HIV
Study (WIHS) cohort.4 In both studies, two-step skin testing was
not performed and the deﬁnition of TST conversion was the same,
making comparisons more legitimate. Differences in conversion
rates between the studies could be due to other factors, including
misclassiﬁcations of positive TST results in either study, since
accurate interpretation of TST is notoriously difﬁcult,12 and
differences in the racial composition of the two cohorts. Although
both cohorts are from socio-economically disadvantaged sectors of
society, non-white or non-black women made up <2% of the WIHS
cohort (listed as ‘other’), while 5.6% of our women were Asian.13
Another possible explanation is that persons enrolled in prospec-
tive cohort studies may be at lower risk for TB infection than the
population at large.
Several limitations of this observational study require mention.
First, as previously noted, two-step testing was not performed at
baseline and therefore we could not differentiate between true
conversion from new TB infection and a booster phenomenon.
Second, induration size was not noted and the TST result was
indicated as being ‘positive’ if 5 mm or ‘negative’ if <5 mm.
Therefore, we could not measure changes in induration size. When
repeat TST testing is conducted, increases of 6 mm are considered
to represent a true biological phenomenon (boosting or conver-
sion) rather than inherent variability of the test due to differences
in administration and reading or non-speciﬁc differences in
biological response to tuberculin.14 The Centers for Disease
Control and Prevention (CDC) guidelines deﬁne a new conversion
in persons undergoing repeat TST testing (generally health
workers) as a 10 mm increase in induration, although no speciﬁcrecommendations are made for repeat testing of HIV-infected
persons.15 For these reasons, small increases in induration size
(e.g., from 3 mm to 6 mm) may have been misclassiﬁed as
conversions instead of expected variability of the test. Finally, this
study was conducted in a single site located in a New York City
public hospital, limiting the generalizability of our data. However,
surveillance data in 2006 indicate that 82% of reported AIDS cases
were among persons residing in urban areas with a population
>500 000, therefore our study is likely to be relevant to the
majority of infected patients in the USA.16
In summary, among HIV-infected patients attending a munici-
pal HIV clinic in New York City, we found a high TST conversion
rate of 1.77 per 100 person-years. Being a foreign-born Asian
individual, having a history of living in a shelter or being homeless,
and an increase in CD4 cell count were independent risk factors for
conversion. Patients in these groups, as well as foreign-born
persons from other high-endemic countries, should be targeted for
baseline two-step TST and annual TST so that appropriate
treatment for LTBI can be prescribed.
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